Literature DB >> 12820687

Assessment of beta cell mass and oxidative peritoneal exudate cells in murine type 1 diabetes using adoptive transfer system.

Satoru Yamada1, Junichiro Irie, Akira Shimada, Keiichi Kodama, Jiro Morimoto, Ryuji Suzuki, Yoichi Oikawa, Takao Saruta.   

Abstract

Because it is controversial how the beta cell mass is reduced during the disease process in type 1 diabetes, we transferred splenocytes from Non-obese diabetic (NOD) to NOD-scid mice and evaluated the relation between the status of the pancreas in donors and the time taken to transfer diabetes to the recipients. We also evaluated the usefulness of assessment of the proportion of oxidative peritoneal exudate cells (PEC) as a novel marker of disease activity in this system. We examined the proportion of oxidative PEC, pancreatic insulin content and pancreatic histology in 16-18-week-old female NOD mice (donors), and transferred their splenocytes into 5-week-old female NOD-scid mice (recipients). After the onset of diabetes in NOD-scid recipients, we assessed the relation between insulin content (or severity of insulitis) of NOD donors and the time taken to transfer diabetes to NOD-scid recipients. The insulin content of "diabetes-prone" donors whose disease status was considered to be just before the onset of diabetes ("malignant" donors) was the same as that of diabetic mice, whereas the insulin content of "diabetes-prone" donors excluding "malignant" donors ("benign" donors) was the same as that of "non-diabetes-prone" donors. Because its proportion of oxidative PEC was inversely correlated with the severity of insulitis, we then evaluated the relation between the proportion of oxidative PEC and the time taken to transfer diabetes. "Malignant" donors had less proportion of oxidative PEC (< 10%), as compared to "benign" and "non-diabetes-prone" donors. These results suggest that a marked reduction of beta cell mass occurs at the very late prediabetic stage, and assessment of the proportion of oxidative PEC is useful to evaluate disease activity in type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820687     DOI: 10.1080/0891693031000079266

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  5 in total

1.  CXC chemokine ligand 10 DNA vaccination plus Complete Freund's Adjuvant reverses hyperglycemia in non-obese diabetic mice.

Authors:  Yoichi Oikawa; Akira Shimada; Yoshifumi Yamada; Yoshiaki Okubo; Takeshi Katsuki; Toshikatsu Shigihara; Jun-Ichi Miyazaki; Shosaku Narumi; Hiroshi Itoh
Journal:  Rev Diabet Stud       Date:  2010-11-10

2.  Acceleration of diabetes development in CXC chemokine receptor 3 (CXCR3)-deficient NOD mice.

Authors:  Y Yamada; Y Okubo; A Shimada; Y Oikawa; S Yamada; S Narumi; K Matsushima; H Itoh
Journal:  Diabetologia       Date:  2012-04-11       Impact factor: 10.122

Review 3.  CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus.

Authors:  Zahra Ahmadi; Mohammad Kazemi Arababadi; Gholamhossin Hassanshahi
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

4.  The role of the CXCL10/CXCR3 system in type 1 diabetes.

Authors:  Akira Shimada; Yoichi Oikawa; Yoshifumi Yamada; Yoshiaki Okubo; Shosaku Narumi
Journal:  Rev Diabet Stud       Date:  2009-08-10

5.  Multidose streptozotocin induction of diabetes in BALB/c mice induces a dominant oxidative macrophage and a conversion of TH1 to TH2 phenotypes during disease progression.

Authors:  Naxin Sun; Guiwen Yang; Heng Zhao; Huub F J Savelkoul; Liguo An
Journal:  Mediators Inflamm       Date:  2005-08-31       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.